Stockscreener 앱 받기
47.94
1.24%
0.5313
Novo Nordisk Adr 주식(NVO)의 최신 뉴스
Non-controlling/minority interest of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Novo Nordisk (NYSE: NVO) repurchases 20,959,179 shares in 2026 - Stock Titan
Zealthy Expands Insurance Coordination for GLP-1 Weight-Loss Medications - GlobeNewswire Inc.
Novo Nordisk updates analyst targets, shares stay in S&P 500 focus - Ad-hoc-news.de
Novo Nordisk wins key South Africa ruling, shares extend obesity-drug lead - Ad-hoc-news.de
Wegovy from Novo Nordisk A/ S (ADR)weekly injection reshapes obesity care - Ad-hoc-news.de
European ADRs Open The Week Higher In US Trading - Finimize
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk A/Sshare repurchase programme - Finansavisen
Novo Nordisk StockAnalyst consensus and GLP-1 momentum - Ad-hoc-news.de
Novo Nordisk (NYSE:NVO) Faces Cyber Breach While Pushing Oral Wegovy Into China - Sahm
Why Novo Nordisk’s Wegovy weekly injection changes daily routines - Ad-hoc-news.de
Why Novo Nordisk’s Ozempic FlexTouch pen keeps changing everyday routines - Ad-hoc-news.de
Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models - Sahm
Novo Nordisk A/ S Stock (DK0062498333): China Wegovy filing puts the stock in focus - AD HOC NEWS
Novo Nordisk (NYSE:NVO) Wins UK Approval For Oral Wegovy In Europe First - Sahm
Novo Nordisk A/ S Stock (DK0062498333): Buyback Update Puts Capital Returns In Focus - Ad-hoc-news.de
Novo Nordisk (NVO) repurchases 19.9M B shares under 2026 plan - Stock Titan
Novo Nordisk A/ S Stock (DK0060534915): Technical picture draws investor focus - AD HOC NEWS
Novo Nordisk’s CagriSema Breakthrough Expands Growth Story Beyond Diabetes and Obesity - Sahm
Novo Nordisk A/S Stock (DK0060534915): Wegovy tablet approval and ADRs in focus after late-week gain - Ad-hoc-news.de
Market news - investments.halifax.co.uk
Novo Nordisk Wegovy pill draws 10,000 UK waitlist ahead of approvalBloomberg - Investing.com Australia
Total operating expenses of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOD - TradingView
Assessing Novo Nordisk (NYSE:NVO) Valuation After Recent Share Weakness And GLP‑1 Growth Questions - simplywall.st
Novo Nordisk CEO Hints Semaglutide Could Be More Than A Weight-Loss Drug: 'A Bit Of A Longevity Game' - Sahm
Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows - Investing.com Nigeria
Novo Nordisk A/S stock (DK0062498333): Ozempic boom meets fresh obesity data and US pricing debate - AD HOC NEWS
European ADRs Started The Week In The Green - Finimize
Novo Nordisk ADR's decline widens rapidly to 3.8%, hitting a new intraday low - Bitget
Novo Nordisk stock falls on ADA conference readthrough - Investing.com
Novo Nordisk Wegovy Trial With Veru Adds Underappreciated Obesity Angle - Sahm
Total operating expenses of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Novo Nordisk A/S stock (DK0062498333): Danish pharma heavyweight steadies after recent pullback - AD HOC NEWS
Novo Nordisk launches Wegovy weight-loss pill in UAE - Investing.com
Novo Nordisk Trial Updates Test Support For Obesity And Diabetes Valuation - Sahm
Novo Nordisk’s Adiposity Franchise Under Siege as CVS Levels the Playing Field and US Pricing Rule - AD HOC NEWS
Novo Nordisk Stock Forecast | Q1 Results and Guidance - Capital.com
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B - TradingView
0.88%
2.04%
자본화:
|
볼륨(24시간):